GLYCEMIC CONTROL AND TREATMENT SATISFACTION USING FINESSE VERSUS PEN FOR INITIATING BOLUS INSULIN DOSING IN TYPE 2 DIABETES MELLITUS PATIENTS NOT ACHIEVING GLYCEMIC TARGETS ON BASAL INSULIN WITH/WITHOUT ANTI-HYPERGLYCEMIC AGENTS

Trial Profile

GLYCEMIC CONTROL AND TREATMENT SATISFACTION USING FINESSE VERSUS PEN FOR INITIATING BOLUS INSULIN DOSING IN TYPE 2 DIABETES MELLITUS PATIENTS NOT ACHIEVING GLYCEMIC TARGETS ON BASAL INSULIN WITH/WITHOUT ANTI-HYPERGLYCEMIC AGENTS

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 04 Dec 2017

At a glance

  • Drugs Insulin aspart (Primary) ; Insulin glargine (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Sponsors Calibra Medical
  • Most Recent Events

    • 04 Dec 2017 This trial has been completed in Germany, according to European Clinical Trials Database
    • 25 Jan 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top